20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Biohaven Ltd. (BHVN) operates in the BIOTECHNOLOGY industry and is headquartered in New Haven, United States with about 274 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, BHVN reported $0M in revenue and ($739M) in net income.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M | $0M | $463M | $0M | — | — |
| Gross Profit | — | ($4M) | ($4M) | ($3M) | ($1M) | $371M | $0M | — | — |
| Gross Margin % | — | — | — | — | — | 80.2% | — | — | — |
| Operating Income (EBIT) | ($567M) | ($745M) | ($885M) | ($436M) | ($568M) | ($219M) | ($115M) | ($479M) | — |
| Operating Margin % | — | — | — | — | — | -47.3% | — | — | — |
| Net Income | ($587M) | ($739M) | ($846M) | ($408M) | ($570M) | ($214M) | ($119M) | ($529M) | — |
| Net Margin % | — | — | — | — | — | -46.2% | — | — | — |
| EBITDA | ($575M) | ($727M) | ($838M) | ($403M) | ($568M) | ($211M) | ($114M) | ($479M) | — |
| Earnings Per Share (EPS) | $-4.65 | $-6.86 | $-9.28 | $-5.73 | $-12.75 | $-5.43 | $-3.01 | $-10.91 | — |
| Shares Outstanding (M) | 151M | 108M | 91M | 71M | 45M | 39M | 39M | 48M | 36M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M | $0M | $0M | $4M | $0M |
| Gross Profit | — | — | ($1M) | ($1M) | — | ($1M) | $2M | ($1M) |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($125M) | ($130M) | ($143M) | ($169M) | ($212M) | ($222M) | ($190M) | ($178M) |
| Operating Margin % | — | — | — | — | — | — | -4951.3% | — |
| Net Income | ($137M) | ($131M) | ($146M) | ($173M) | ($198M) | ($222M) | ($187M) | ($160M) |
| Net Margin % | — | — | — | — | — | — | -4870.8% | — |
| EBITDA | ($132M) | ($128M) | ($143M) | ($172M) | ($196M) | ($219M) | ($184M) | ($158M) |
| Earnings Per Share (EPS) | $-0.91 | $-0.88 | $-1.21 | $-1.64 | $-1.94 | $-2.17 | $-1.85 | $-1.70 |
| Shares Outstanding (M) | 151M | 148M | 120M | 106M | 102M | 102M | 101M | 94M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($511M) | ($609M) | ($582M) | ($332M) | ($298M) | ($146M) | ($76M) | ($377M) | ($197M) | ($95M) |
| Capital Expenditures (CapEx) | $0M | $1M | $4M | $3M | $41M | $1M | $3M | $3M | $4M | $1M |
| Free Cash Flow (FCF) | ($512M) | ($610M) | ($587M) | ($335M) | ($339M) | ($147M) | ($79M) | ($380M) | ($201M) | ($95M) |
| FCF Margin % | — | — | — | — | — | -31.7% | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($85M) | ($150M) | ($131M) | ($146M) | ($168M) | ($165M) | ($171M) | ($141M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $1M |
| Free Cash Flow (FCF) | ($86M) | ($150M) | ($131M) | ($146M) | ($168M) | ($166M) | ($171M) | ($142M) |
| FCF Margin % | — | — | — | — | — | — | -4452.3% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $371M | $451M | $615M | $513M | $662M | $142M | $111M | $344M | $290M | $147M |
| Cash & Cash Equivalents | $238M | $230M | $99M | $248M | $205M | $76M | $83M | $317M | $264M | $131M |
| Total Liabilities | $359M | $399M | $192M | $85M | $123M | $47M | $35M | $352M | $139M | $15M |
| Total Debt (Short + Long-Term) | $5M | $245M | $4M | $3M | $3M | $627M | $1M | $0M | $0M | $0M |
| Total Shareholders' Equity | $12M | $52M | $423M | $428M | $539M | $95M | $77M | ($7M) | $151M | $132M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BHVN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms